Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?

Liquid biopsy assays for minimal residual disease (MRD) are used to monitor and inform oncological treatment and predict the risk of relapse in cancer patients. To-date, most MRD assay development has focused on targeting somatic mutations. However, epigenetic changes are more frequent and universal...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Andrew D., Ross, Jason P., Ma, Chenkai, Fung, Kim Y. C., Locke, Warwick J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110851/
https://www.ncbi.nlm.nih.gov/pubmed/37081990
http://dx.doi.org/10.3389/fonc.2023.1103797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110851/
https://www.ncbi.nlm.nih.gov/pubmed/37081990
http://dx.doi.org/10.3389/fonc.2023.1103797

Ejemplares similares